{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "29", "@timestamp": "2020-03-29T13:37:04.000004-04:00", "@year": "2020", "@month": "03"}, "ait:date-sort": {"@day": "01", "@year": "2017", "@month": "03"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": [{"xocs:funding-agency-matched-string": "Royal College of Physicians of Thailand", "xocs:funding-agency-acronym": "RACP", "xocs:funding-agency": "Royal Australasian College of Physicians", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100001232", "xocs:funding-agency-country": "http://sws.geonames.org/2077456/"}, {"xocs:funding-agency-matched-string": "Thailand Research Fund", "xocs:funding-agency-acronym": "TRF", "xocs:funding-agency": "Thailand Research Fund", "xocs:funding-id": [{"$": "RSA5380002"}, {"$": "TRG-5780304"}], "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100004396", "xocs:funding-agency-country": "http://sws.geonames.org/1605651/"}, {"xocs:funding-agency-matched-string": "National Research Council of Thailand", "xocs:funding-agency-acronym": "NRCT", "xocs:funding-agency": "National Research Council of Thailand", "xocs:funding-id": "RES_54_143_30_018", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100004704", "xocs:funding-agency-country": "http://sws.geonames.org/1605651/"}], "xocs:funding-addon-generated-timestamp": "2021-02-02T07:32:47.914537Z", "xocs:funding-text": "Funding: This work was supported by The Thailand Research Fund [grant nos. TRG-5780304 and RSA5380002], The Royal College of Physicians of Thailand, and The National Research Council of Thailand [grant no. RES_54_143_30_018].", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "postal-code": "50200", "@afid": "60000881", "@country": "tha", "city": "Chiang Mai", "organization": [{"$": "Department of Pharmaceutical Care"}, {"$": "Faculty of Pharmacy"}, {"$": "Chiang Mai University"}], "affiliation-id": {"@afid": "60000881", "@dptid": "103084327"}, "@dptid": "103084327"}, "author": [{"ce:given-name": "Baralee", "preferred-name": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, "@seq": "1", "ce:initials": "B.", "@_fa": "true", "@type": "auth", "ce:surname": "Punyawudho", "@auid": "23976628300", "ce:indexed-name": "Punyawudho B."}]}, {"affiliation": {"country": "Thailand", "@afid": "60016965", "@country": "tha", "city": "Bangkok", "organization": [{"$": "HIV-NAT"}, {"$": "Thai Red Cross AIDS Research Centre"}], "affiliation-id": [{"@afid": "60016965"}, {"@afid": "60031780"}]}, "author": [{"ce:given-name": "Narukjaporn", "preferred-name": {"ce:given-name": "Narukjaporn", "ce:initials": "N.", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}, "@seq": "2", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Thammajaruk", "@auid": "36451572800", "ce:indexed-name": "Thammajaruk N."}, {"ce:given-name": "Kiat", "preferred-name": {"ce:given-name": "Kiat", "ce:initials": "K.", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, "@seq": "3", "ce:initials": "K.", "@date-locked": "2017-07-19T12:19:16.967", "@_fa": "true", "@type": "auth", "ce:surname": "Ruxrungtham", "@auid": "7004208798", "ce:indexed-name": "Ruxrungtham K."}, {"ce:given-name": "Anchalee", "preferred-name": {"ce:given-name": "Anchalee", "ce:initials": "A.", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, "@seq": "4", "ce:initials": "A.", "@date-locked": "2018-07-27T21:17:03.882", "@_fa": "true", "@type": "auth", "ce:surname": "Avihingsanon", "@auid": "57196347321", "ce:indexed-name": "Avihingsanon A."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Medicine"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "113019942"}, "@dptid": "113019942"}, "author": [{"ce:given-name": "Kiat", "preferred-name": {"ce:given-name": "Kiat", "ce:initials": "K.", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, "@seq": "3", "ce:initials": "K.", "@date-locked": "2017-07-19T12:19:16.967", "@_fa": "true", "@type": "auth", "ce:surname": "Ruxrungtham", "@auid": "7004208798", "ce:indexed-name": "Ruxrungtham K."}, {"ce:given-name": "Anchalee", "preferred-name": {"ce:given-name": "Anchalee", "ce:initials": "A.", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, "@seq": "4", "ce:initials": "A.", "@date-locked": "2018-07-27T21:17:03.882", "@_fa": "true", "@type": "auth", "ce:surname": "Avihingsanon", "@auid": "57196347321", "ce:indexed-name": "Avihingsanon A."}]}], "citation-title": "Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients", "abstracts": "\u00a9 2017 Elsevier B.V. and International Society of ChemotherapyThere is evidence that Thai patients receiving standard doses of ritonavir (RTV)-boosted atazanavir (ATV/r) have high exposure to atazanavir (ATV) leading to a higher risk of toxicity. A lower dose of ATV/r may provide adequate exposure in this population. However, pharmacokinetic data on ATV/r in Thai patients required for dose adjustment are limited. This study aimed to develop a population pharmacokinetic model of ATV/r and to determine the influence of patient characteristics on ATV pharmacokinetics. Monte Carlo simulations were performed to estimate the proportion of patients achieving target ATV trough concentration (Ctrough) with the standard ATV/r dose of 300/100 mg and a low dose of 200/100 mg once daily (OD). A total of 127 Thai HIV-infected patients were included in this study. One random blood sample was collected to determine ATV and RTV concentrations at each clinic visit from 100 patients. Intensive data from 27 patients enrolled in previous studies were also included. Data were analysed using the non-linear mixed-effects modelling approach. A one-compartment model with first-order absorption and elimination and absorption lag time best described the data. The population mean clearance of ATV/r was 4.93 L/h in female patients and was 28.7% higher in male patients. Simulation results showed a higher proportion of patients achieving ATV Ctrough within the target range with ATV/r 200/100 mg compared with 300/100 mg. The 200/100 mg OD dose of ATV/r provides adequate ATV exposure in Thai HIV-infected patients. Therefore, a lower dose of ATV/r should be considered for Thai and Asian populations.", "correspondence": {"affiliation": {"country": "Thailand", "postal-code": "50200", "@country": "tha", "city": "Chiang Mai", "organization": [{"$": "Department of Pharmaceutical Care"}, {"$": "Faculty of Pharmacy"}, {"$": "Chiang Mai University"}]}, "person": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "Atazanavir", "@xml:lang": "eng"}, {"$": "Dose optimisation", "@xml:lang": "eng"}, {"$": "HIV-infected patients", "@xml:lang": "eng"}, {"$": "NONMEM", "@xml:lang": "eng"}, {"$": "Population pharmacokinetics", "@xml:lang": "eng"}, {"$": "Thai patients", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "www.elsevier.com/locate/ijantimicag", "@type": "email"}}, "translated-sourcetitle": {"$": "International Journal of Antimicrobial Agents", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "49", "@issue": "3"}, "pagerange": {"@first": "327", "@last": "332"}}, "@type": "j", "sourcetitle": "International Journal of Antimicrobial Agents", "publicationdate": {"month": "03", "year": "2017", "date-text": {"@xfab-added": "true", "$": "1 March 2017"}, "day": "01"}, "codencode": "IAAGE", "sourcetitle-abbrev": "Int. J. Antimicrob. Agents", "@country": "nld", "issn": [{"$": "18727913", "@type": "electronic"}, {"$": "09248579", "@type": "print"}], "publicationyear": {"@first": "2017"}, "publisher": {"publishername": "Elsevier B.V."}, "@srcid": "19757"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "CABSCLASS", "classification": {"classification-code": "99", "classification-description": "General"}}, {"@type": "EMCLASS", "classification": [{"classification-code": "26", "classification-description": "Immunology, Serology and Transplantation"}, {"classification-code": "30", "classification-description": "Clinical and Experimental Pharmacology"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "4", "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"}]}, {"@type": "ASJC", "classification": [{"$": "2726"}, {"$": "2725"}, {"$": "2736"}]}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "198904-31-3", "chemical-name": "atazanavir"}, {"cas-registry-number": "69655-05-6", "chemical-name": "didanosine"}, {"cas-registry-number": "154598-52-4", "chemical-name": "efavirenz"}, {"cas-registry-number": [{"$": "137530-41-7"}, {"$": "143491-54-7"}, {"$": "143491-57-0"}], "chemical-name": "emtricitabine"}, {"cas-registry-number": [{"$": "150378-17-9"}, {"$": "157810-81-6"}, {"$": "180683-37-8"}], "chemical-name": "indinavir"}, {"cas-registry-number": [{"$": "134678-17-4"}, {"$": "134680-32-3"}], "chemical-name": "lamivudine"}, {"cas-registry-number": "192725-17-0", "chemical-name": "lopinavir"}, {"cas-registry-number": "155213-67-5", "chemical-name": "ritonavir"}, {"cas-registry-number": [{"$": "127779-20-8"}, {"$": "149845-06-7"}], "chemical-name": "saquinavir"}, {"cas-registry-number": [{"$": "147127-19-3"}, {"$": "147127-20-6"}], "chemical-name": "tenofovir"}, {"cas-registry-number": "30516-87-1", "chemical-name": "zidovudine"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Anti-HIV Agents"}, {"chemical-name": "Atazanavir Sulfate"}, {"chemical-name": "Ritonavir"}]}]}}, "grantlist": {"@complete": "y", "grant-text": {"$": "Funding: This work was supported by The Thailand Research Fund [grant nos. TRG-5780304 and RSA5380002], The Royal College of Physicians of Thailand, and The National Research Council of Thailand [grant no. RES_54_143_30_018].", "@xml:lang": "eng"}, "grant": [{"grant-id": "RES_54_143_30_018", "grant-acronym": "NRCT", "grant-agency": "National Research Council of Thailand"}, {"grant-id": "RSA5380002", "grant-acronym": "TRF", "grant-agency": "Thailand Research Fund"}, {"grant-id": "TRG-5780304", "grant-acronym": "TRF", "grant-agency": "Thailand Research Fund"}]}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "CABS"}, {"$": "EMBASE"}, {"$": "MEDL"}, {"$": "REAXYS"}, {"$": "REAXYSCAR"}, {"$": "RMC"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "28", "@timestamp": "BST 12:49:17", "@year": "2017", "@month": "03"}}, "itemidlist": {"itemid": [{"$": "614278156", "@idtype": "PUI"}, {"$": "2017037757", "@idtype": "CABS"}, {"$": "660576102", "@idtype": "CAR-ID"}, {"$": "20170088993", "@idtype": "EMBASE"}, {"$": "28109702", "@idtype": "MEDL"}, {"$": "2017024194", "@idtype": "REAXYS"}, {"$": "20170214151", "@idtype": "REAXYSCAR"}, {"$": "2017035719", "@idtype": "RMC"}, {"$": "85011066657", "@idtype": "SCP"}, {"$": "85011066657", "@idtype": "SGR"}, {"$": "614914155", "@idtype": "PUIsecondary"}], "ce:pii": "S0924857917300122", "ce:doi": "10.1016/j.ijantimicag.2016.11.019"}}, "tail": {"bibliography": {"@refcount": "42", "reference": [{"ref-fulltext": "[1] Manosuthi, W., Ongwandee, S., Bhakeecheep, S., Leechawengwongs, M., Ruxrungtham, K., Phanuphak, P., et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther, 12, 2015, 12.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand"}, "refd-itemidlist": {"itemid": {"$": "84928230979", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12"}, "pagerange": {"@first": "12"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Manosuthi", "ce:indexed-name": "Manosuthi W."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Ongwandee", "ce:indexed-name": "Ongwandee S."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Bhakeecheep", "ce:indexed-name": "Bhakeecheep S."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Leechawengwongs", "ce:indexed-name": "Leechawengwongs M."}, {"@seq": "5", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Phanuphak", "ce:indexed-name": "Phanuphak P."}], "et-al": null}, "ref-sourcetitle": "AIDS Res Ther"}}, {"ref-fulltext": "[2] Le Tiec, C., Barrail, A., Goujard, C., Taburet, A.M., Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 44 (2005), 1035\u20131050.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir"}, "refd-itemidlist": {"itemid": {"$": "25144448034", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "44"}, "pagerange": {"@first": "1035", "@last": "1050"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Le Tiec", "ce:indexed-name": "Le Tiec C."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Barrail", "ce:indexed-name": "Barrail A."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Goujard", "ce:indexed-name": "Goujard C."}, {"@seq": "4", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Taburet", "ce:indexed-name": "Taburet A.M."}]}, "ref-sourcetitle": "Clin Pharmacokinet"}}, {"ref-fulltext": "[3] Loutfy, M.R., Walmsley, S.L., Klein, M.B., Raboud, J., Tseng, A.L., Blitz, S.L., et al. Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. BMC Infect Dis, 13, 2013, 256.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study"}, "refd-itemidlist": {"itemid": {"$": "84878362121", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "13"}, "pagerange": {"@first": "256"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.R.", "@_fa": "true", "ce:surname": "Loutfy", "ce:indexed-name": "Loutfy M.R."}, {"@seq": "2", "ce:initials": "S.L.", "@_fa": "true", "ce:surname": "Walmsley", "ce:indexed-name": "Walmsley S.L."}, {"@seq": "3", "ce:initials": "M.B.", "@_fa": "true", "ce:surname": "Klein", "ce:indexed-name": "Klein M.B."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Raboud", "ce:indexed-name": "Raboud J."}, {"@seq": "5", "ce:initials": "A.L.", "@_fa": "true", "ce:surname": "Tseng", "ce:indexed-name": "Tseng A.L."}, {"@seq": "6", "ce:initials": "S.L.", "@_fa": "true", "ce:surname": "Blitz", "ce:indexed-name": "Blitz S.L."}], "et-al": null}, "ref-sourcetitle": "BMC Infect Dis"}}, {"ref-fulltext": "[4] Brundage, R.C., Yong, F.H., Fenton, T., Spector, S.A., Starr, S.E., Fletcher, C.V., Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 48 (2004), 979\u2013984.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "1442349117", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "48"}, "pagerange": {"@first": "979", "@last": "984"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.C.", "@_fa": "true", "ce:surname": "Brundage", "ce:indexed-name": "Brundage R.C."}, {"@seq": "2", "ce:initials": "F.H.", "@_fa": "true", "ce:surname": "Yong", "ce:indexed-name": "Yong F.H."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Fenton", "ce:indexed-name": "Fenton T."}, {"@seq": "4", "ce:initials": "S.A.", "@_fa": "true", "ce:surname": "Spector", "ce:indexed-name": "Spector S.A."}, {"@seq": "5", "ce:initials": "S.E.", "@_fa": "true", "ce:surname": "Starr", "ce:indexed-name": "Starr S.E."}, {"@seq": "6", "ce:initials": "C.V.", "@_fa": "true", "ce:surname": "Fletcher", "ce:indexed-name": "Fletcher C.V."}]}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "[5] la Porte, C.J.L., Back, D., Blaschke, T., Boucher, C.A.B., Fletcher, C.V., Gerber, J., et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 3 (2006), 4\u201314.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Updated guideline to perform therapeutic drug monitoring for antiretroviral agents"}, "refd-itemidlist": {"itemid": {"$": "34249876574", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "3"}, "pagerange": {"@first": "4", "@last": "14"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.J.L.", "@_fa": "true", "ce:surname": "la Porte", "ce:indexed-name": "la Porte C.J.L."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Back", "ce:indexed-name": "Back D."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Blaschke", "ce:indexed-name": "Blaschke T."}, {"@seq": "4", "ce:initials": "C.A.B.", "@_fa": "true", "ce:surname": "Boucher", "ce:indexed-name": "Boucher C.A.B."}, {"@seq": "5", "ce:initials": "C.V.", "@_fa": "true", "ce:surname": "Fletcher", "ce:indexed-name": "Fletcher C.V."}, {"@seq": "6", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Gerber", "ce:indexed-name": "Gerber J."}], "et-al": null}, "ref-sourcetitle": "Rev Antiviral Ther"}}, {"ref-fulltext": "[6] Colombo, S., Buclin, T., Cavassini, M., Decosterd, L.A., Telenti, A., Biollaz, J., et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 50 (2006), 3801\u20133808.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection"}, "refd-itemidlist": {"itemid": {"$": "33750597597", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "50"}, "pagerange": {"@first": "3801", "@last": "3808"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Colombo", "ce:indexed-name": "Colombo S."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Buclin", "ce:indexed-name": "Buclin T."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Cavassini", "ce:indexed-name": "Cavassini M."}, {"@seq": "4", "ce:initials": "L.A.", "@_fa": "true", "ce:surname": "Decosterd", "ce:indexed-name": "Decosterd L.A."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Telenti", "ce:indexed-name": "Telenti A."}, {"@seq": "6", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Biollaz", "ce:indexed-name": "Biollaz J."}], "et-al": null}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "[7] Winston, A., Bloch, M., Carr, A., Amin, J., Mallon, P.W., Ray, J., et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 56 (2005), 380\u2013387.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "23844481944", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56"}, "pagerange": {"@first": "380", "@last": "387"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Winston", "ce:indexed-name": "Winston A."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Bloch", "ce:indexed-name": "Bloch M."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Carr", "ce:indexed-name": "Carr A."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Amin", "ce:indexed-name": "Amin J."}, {"@seq": "5", "ce:initials": "P.W.", "@_fa": "true", "ce:surname": "Mallon", "ce:indexed-name": "Mallon P.W."}, {"@seq": "6", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Ray", "ce:indexed-name": "Ray J."}], "et-al": null}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "[8] DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS) https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 20 May 2015].", "@id": "8", "ref-info": {"ref-website": {"ce:e-address": {"$": "https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf", "@type": "email"}}, "ref-title": {"ref-titletext": "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"}, "refd-itemidlist": {"itemid": {"$": "84873974137", "@idtype": "SGR"}}, "ref-text": "Department of Health and Human Services (DHHS) [Accessed 20 May 2015]", "ref-authors": {"author": [{"@seq": "1", "@_fa": "true", "ce:surname": "DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents", "ce:indexed-name": "DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents"}]}}}, {"ref-fulltext": "[9] Avihingsanon, A., Apornpong, T., Kerr, S.J., Make-a-nantawat, W., Thammajaruk, N., Phonphithak, S., et al. Low-dose ritonavir-boosted atazanavir (200/100 mg) maintained a high virological efficacy up to 4 years in treatment-experienced HIV-1 infected adults: a prospective cohort study from Asia. J AIDS Clin Res, 6, 2015, 460.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Low-dose ritonavir-boosted atazanavir (200/100 mg) maintained a high virological efficacy up to 4 years in treatment-experienced HIV-1 infected adults: a prospective cohort study from Asia"}, "refd-itemidlist": {"itemid": {"$": "84994880704", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6"}, "pagerange": {"@first": "460"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Apornpong", "ce:indexed-name": "Apornpong T."}, {"@seq": "3", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, {"@seq": "4", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Make-a-nantawat", "ce:indexed-name": "Make-a-nantawat W."}, {"@seq": "5", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Phonphithak", "ce:indexed-name": "Phonphithak S."}], "et-al": null}, "ref-sourcetitle": "J AIDS Clin Res"}}, {"ref-fulltext": "[10] Avihingsanon, A., van der Lugt, J., Kerr, S.J., Gorowara, M., Chanmano, S., Ohata, P., et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 85 (2009), 402\u2013408.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults"}, "refd-itemidlist": {"itemid": {"$": "62649107112", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "85"}, "pagerange": {"@first": "402", "@last": "408"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "van der Lugt", "ce:indexed-name": "van der Lugt J."}, {"@seq": "3", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gorowara", "ce:indexed-name": "Gorowara M."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Chanmano", "ce:indexed-name": "Chanmano S."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ohata", "ce:indexed-name": "Ohata P."}], "et-al": null}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "[11] Chetchotisakd, P., Anunnatsiri, S., Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand. J Acquir Immune Defic Syndr 49 (2008), 230\u2013231.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand"}, "refd-itemidlist": {"itemid": {"$": "55249090146", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "49"}, "pagerange": {"@first": "230", "@last": "231"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Chetchotisakd", "ce:indexed-name": "Chetchotisakd P."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Anunnatsiri", "ce:indexed-name": "Anunnatsiri S."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "[12] Kerr, S.J., Punyawudho, B., Thammajaruk, N., Colbers, A., Chaiyahong, P., Phonphithak, S., et al. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy. AIDS Res Hum Retroviruses 31 (2015), 368\u2013374.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "84951574879", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "31"}, "pagerange": {"@first": "368", "@last": "374"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Colbers", "ce:indexed-name": "Colbers A."}, {"@seq": "5", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Chaiyahong", "ce:indexed-name": "Chaiyahong P."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Phonphithak", "ce:indexed-name": "Phonphithak S."}], "et-al": null}, "ref-sourcetitle": "AIDS Res Hum Retroviruses"}}, {"ref-fulltext": "[13] Droste, J.A., Verweij-Van Wissen, C.P., Burger, D.M., Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 25 (2003), 393\u2013399.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography"}, "refd-itemidlist": {"itemid": {"$": "0038103469", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "25"}, "pagerange": {"@first": "393", "@last": "399"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Droste", "ce:indexed-name": "Droste J.A."}, {"@seq": "2", "ce:initials": "C.P.", "@_fa": "true", "ce:surname": "Verweij-Van Wissen", "ce:indexed-name": "Verweij-Van Wissen C.P."}, {"@seq": "3", "ce:initials": "D.M.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D.M."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "[14] Burger, D., Teulen, M., Eerland, J., Harteveld, A., Aarnoutse, R., Touw, D., The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program. Ther Drug Monit 33 (2011), 239\u2013243.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program"}, "refd-itemidlist": {"itemid": {"$": "79953216672", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "33"}, "pagerange": {"@first": "239", "@last": "243"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger D."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Teulen", "ce:indexed-name": "Teulen M."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Eerland", "ce:indexed-name": "Eerland J."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Harteveld", "ce:indexed-name": "Harteveld A."}, {"@seq": "5", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Aarnoutse", "ce:indexed-name": "Aarnoutse R."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Touw", "ce:indexed-name": "Touw D."}]}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "[15] Savic, R.M., Barrail-Tran, A., Duval, X., Nembot, G., Panhard, X., Descamps, D., et al. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther 92 (2012), 575\u2013583.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "84867883813", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "92"}, "pagerange": {"@first": "575", "@last": "583"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Savic", "ce:indexed-name": "Savic R.M."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Barrail-Tran", "ce:indexed-name": "Barrail-Tran A."}, {"@seq": "3", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Duval", "ce:indexed-name": "Duval X."}, {"@seq": "4", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Nembot", "ce:indexed-name": "Nembot G."}, {"@seq": "5", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Panhard", "ce:indexed-name": "Panhard X."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Descamps", "ce:indexed-name": "Descamps D."}], "et-al": null}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "[16] Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., et al. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr 62 (2013), 60\u201366.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies"}, "refd-itemidlist": {"itemid": {"$": "84872088973", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62"}, "pagerange": {"@first": "60", "@last": "66"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Schipani", "ce:indexed-name": "Schipani A."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Dickinson", "ce:indexed-name": "Dickinson L."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Boffito", "ce:indexed-name": "Boffito M."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Austin", "ce:indexed-name": "Austin R."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Owen", "ce:indexed-name": "Owen A."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Back", "ce:indexed-name": "Back D."}], "et-al": null}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "[17] Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., et al. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother 63 (2009), 1233\u20131243.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers"}, "refd-itemidlist": {"itemid": {"$": "65749113553", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "63"}, "pagerange": {"@first": "1233", "@last": "1243"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Dickinson", "ce:indexed-name": "Dickinson L."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Boffito", "ce:indexed-name": "Boffito M."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Back", "ce:indexed-name": "Back D."}, {"@seq": "4", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Waters", "ce:indexed-name": "Waters L."}, {"@seq": "5", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Else", "ce:indexed-name": "Else L."}, {"@seq": "6", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Davies", "ce:indexed-name": "Davies G."}], "et-al": null}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "[18] Jonsson, E.N., Karlsson, M.O., Xpose\u2014an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58 (1999), 51\u201364.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "1999"}, "ref-title": {"ref-titletext": "Xpose\u2014an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM"}, "refd-itemidlist": {"itemid": {"$": "0002322365", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58"}, "pagerange": {"@first": "51", "@last": "64"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.N.", "@_fa": "true", "ce:surname": "Jonsson", "ce:indexed-name": "Jonsson E.N."}, {"@seq": "2", "ce:initials": "M.O.", "@_fa": "true", "ce:surname": "Karlsson", "ce:indexed-name": "Karlsson M.O."}]}, "ref-sourcetitle": "Comput Methods Programs Biomed"}}, {"ref-fulltext": "[19] Ette, E.I., Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37 (1997), 486\u2013495.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "1997"}, "ref-title": {"ref-titletext": "Stability and performance of a population pharmacokinetic model"}, "refd-itemidlist": {"itemid": {"$": "0030953226", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "37"}, "pagerange": {"@first": "486", "@last": "495"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.I.", "@_fa": "true", "ce:surname": "Ette", "ce:indexed-name": "Ette E.I."}]}, "ref-sourcetitle": "J Clin Pharmacol"}}, {"ref-fulltext": "[20] Ette, E.I., Williams, P.J., Kim, Y.H., Lane, J.R., Liu, M.J., Capparelli, E.V., Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43 (2003), 610\u2013623.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Model appropriateness and population pharmacokinetic modeling"}, "refd-itemidlist": {"itemid": {"$": "0038243538", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "43"}, "pagerange": {"@first": "610", "@last": "623"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.I.", "@_fa": "true", "ce:surname": "Ette", "ce:indexed-name": "Ette E.I."}, {"@seq": "2", "ce:initials": "P.J.", "@_fa": "true", "ce:surname": "Williams", "ce:indexed-name": "Williams P.J."}, {"@seq": "3", "ce:initials": "Y.H.", "@_fa": "true", "ce:surname": "Kim", "ce:indexed-name": "Kim Y.H."}, {"@seq": "4", "ce:initials": "J.R.", "@_fa": "true", "ce:surname": "Lane", "ce:indexed-name": "Lane J.R."}, {"@seq": "5", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Liu", "ce:indexed-name": "Liu M.J."}, {"@seq": "6", "ce:initials": "E.V.", "@_fa": "true", "ce:surname": "Capparelli", "ce:indexed-name": "Capparelli E.V."}]}, "ref-sourcetitle": "J Clin Pharmacol"}}, {"ref-fulltext": "[21] Jadhav, P.R., Gobburu, J.V., A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 7 (2005), E523\u201331.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "A new equivalence based metric for predictive check to qualify mixed-effects models"}, "refd-itemidlist": {"itemid": {"$": "33644813010", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "E523", "@last": "31"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.R.", "@_fa": "true", "ce:surname": "Jadhav", "ce:indexed-name": "Jadhav P.R."}, {"@seq": "2", "ce:initials": "J.V.", "@_fa": "true", "ce:surname": "Gobburu", "ce:indexed-name": "Gobburu J.V."}]}, "ref-sourcetitle": "AAPS J"}}, {"ref-fulltext": "[22] Yano, Y., Beal, S.L., Sheiner, L.B., Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28 (2001), 171\u2013192.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check"}, "refd-itemidlist": {"itemid": {"$": "0034764915", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28"}, "pagerange": {"@first": "171", "@last": "192"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Yano", "ce:indexed-name": "Yano Y."}, {"@seq": "2", "ce:initials": "S.L.", "@_fa": "true", "ce:surname": "Beal", "ce:indexed-name": "Beal S.L."}, {"@seq": "3", "ce:initials": "L.B.", "@_fa": "true", "ce:surname": "Sheiner", "ce:indexed-name": "Sheiner L.B."}]}, "ref-sourcetitle": "J Pharmacokinet Pharmacodyn"}}, {"ref-fulltext": "[23] Amadasi, S., Odolini, S., Foca, E., Panzali, A., Cerini, C., Lonati, L., et al. Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients. Curr HIV Res 11 (2013), 642\u2013646.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients"}, "refd-itemidlist": {"itemid": {"$": "84900469083", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "11"}, "pagerange": {"@first": "642", "@last": "646"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Amadasi", "ce:indexed-name": "Amadasi S."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Odolini", "ce:indexed-name": "Odolini S."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Foca", "ce:indexed-name": "Foca E."}, {"@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Panzali", "ce:indexed-name": "Panzali A."}, {"@seq": "5", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Cerini", "ce:indexed-name": "Cerini C."}, {"@seq": "6", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Lonati", "ce:indexed-name": "Lonati L."}], "et-al": null}, "ref-sourcetitle": "Curr HIV Res"}}, {"ref-fulltext": "[24] Venuto, C.S., Mollan, K., Ma, Q., Daar, E.S., Sax, P.E., Fischl, M., et al. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother 69 (2014), 3300\u20133310.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202"}, "refd-itemidlist": {"itemid": {"$": "84960146946", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "69"}, "pagerange": {"@first": "3300", "@last": "3310"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.S.", "@_fa": "true", "ce:surname": "Venuto", "ce:indexed-name": "Venuto C.S."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Mollan", "ce:indexed-name": "Mollan K."}, {"@seq": "3", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Ma", "ce:indexed-name": "Ma Q."}, {"@seq": "4", "ce:initials": "E.S.", "@_fa": "true", "ce:surname": "Daar", "ce:indexed-name": "Daar E.S."}, {"@seq": "5", "ce:initials": "P.E.", "@_fa": "true", "ce:surname": "Sax", "ce:indexed-name": "Sax P.E."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Fischl", "ce:indexed-name": "Fischl M."}], "et-al": null}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "[25] Gandhi, M., Aweeka, F., Greenblatt, R.M., Blaschke, T.F., Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44 (2004), 499\u2013523.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Sex differences in pharmacokinetics and pharmacodynamics"}, "refd-itemidlist": {"itemid": {"$": "1342302371", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "44"}, "pagerange": {"@first": "499", "@last": "523"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gandhi", "ce:indexed-name": "Gandhi M."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Aweeka", "ce:indexed-name": "Aweeka F."}, {"@seq": "3", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Greenblatt", "ce:indexed-name": "Greenblatt R.M."}, {"@seq": "4", "ce:initials": "T.F.", "@_fa": "true", "ce:surname": "Blaschke", "ce:indexed-name": "Blaschke T.F."}]}, "ref-sourcetitle": "Annu Rev Pharmacol Toxicol"}}, {"ref-fulltext": "[26] Shiau, S., Kuhn, L., Strehlau, R., Martens, L., McIlleron, H., Meredith, S., et al. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr, 14, 2014, 39.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment"}, "refd-itemidlist": {"itemid": {"$": "84893710579", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14"}, "pagerange": {"@first": "39"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Shiau", "ce:indexed-name": "Shiau S."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Kuhn", "ce:indexed-name": "Kuhn L."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Strehlau", "ce:indexed-name": "Strehlau R."}, {"@seq": "4", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Martens", "ce:indexed-name": "Martens L."}, {"@seq": "5", "ce:initials": "H.", "@_fa": "true", "ce:surname": "McIlleron", "ce:indexed-name": "McIlleron H."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Meredith", "ce:indexed-name": "Meredith S."}], "et-al": null}, "ref-sourcetitle": "BMC Pediatr"}}, {"ref-fulltext": "[27] Umeh, O.C., Currier, J.S., Park, J.G., Cramer, Y., Hermes, A.E., Fletcher, C.V., Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol 51 (2011), 1665\u20131673.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men"}, "refd-itemidlist": {"itemid": {"$": "79959216019", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "51"}, "pagerange": {"@first": "1665", "@last": "1673"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "O.C.", "@_fa": "true", "ce:surname": "Umeh", "ce:indexed-name": "Umeh O.C."}, {"@seq": "2", "ce:initials": "J.S.", "@_fa": "true", "ce:surname": "Currier", "ce:indexed-name": "Currier J.S."}, {"@seq": "3", "ce:initials": "J.G.", "@_fa": "true", "ce:surname": "Park", "ce:indexed-name": "Park J.G."}, {"@seq": "4", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Cramer", "ce:indexed-name": "Cramer Y."}, {"@seq": "5", "ce:initials": "A.E.", "@_fa": "true", "ce:surname": "Hermes", "ce:indexed-name": "Hermes A.E."}, {"@seq": "6", "ce:initials": "C.V.", "@_fa": "true", "ce:surname": "Fletcher", "ce:indexed-name": "Fletcher C.V."}]}, "ref-sourcetitle": "J Clin Pharmacol"}}, {"ref-fulltext": "[28] Cleijsen, R.M., van de Ende, M.E., Kroon, F.P., Lunel, F.V., Koopmans, P.P., Gras, L., et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 60 (2007), 897\u2013900.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice"}, "refd-itemidlist": {"itemid": {"$": "34548784342", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "60"}, "pagerange": {"@first": "897", "@last": "900"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Cleijsen", "ce:indexed-name": "Cleijsen R.M."}, {"@seq": "2", "ce:initials": "M.E.", "@_fa": "true", "ce:surname": "van de Ende", "ce:indexed-name": "van de Ende M.E."}, {"@seq": "3", "ce:initials": "F.P.", "@_fa": "true", "ce:surname": "Kroon", "ce:indexed-name": "Kroon F.P."}, {"@seq": "4", "ce:initials": "F.V.", "@_fa": "true", "ce:surname": "Lunel", "ce:indexed-name": "Lunel F.V."}, {"@seq": "5", "ce:initials": "P.P.", "@_fa": "true", "ce:surname": "Koopmans", "ce:indexed-name": "Koopmans P.P."}, {"@seq": "6", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Gras", "ce:indexed-name": "Gras L."}], "et-al": null}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "[29] Solas, C., Gagnieu, M.C., Ravaux, I., Drogoul, M.P., Lafeuillade, A., Mokhtari, S., et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit 30 (2008), 670\u2013673.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients"}, "refd-itemidlist": {"itemid": {"$": "57749095660", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "30"}, "pagerange": {"@first": "670", "@last": "673"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Solas", "ce:indexed-name": "Solas C."}, {"@seq": "2", "ce:initials": "M.C.", "@_fa": "true", "ce:surname": "Gagnieu", "ce:indexed-name": "Gagnieu M.C."}, {"@seq": "3", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Ravaux", "ce:indexed-name": "Ravaux I."}, {"@seq": "4", "ce:initials": "M.P.", "@_fa": "true", "ce:surname": "Drogoul", "ce:indexed-name": "Drogoul M.P."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Lafeuillade", "ce:indexed-name": "Lafeuillade A."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Mokhtari", "ce:indexed-name": "Mokhtari S."}], "et-al": null}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "[30] D'Avolio, A., Carcieri, C., Cusato, J., Simiele, M., Calcagno, A., Allegra, S., et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother 69 (2014), 3061\u20133066.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms"}, "refd-itemidlist": {"itemid": {"$": "84923065347", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "69"}, "pagerange": {"@first": "3061", "@last": "3066"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "D'Avolio", "ce:indexed-name": "D'Avolio A."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Carcieri", "ce:indexed-name": "Carcieri C."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Cusato", "ce:indexed-name": "Cusato J."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Simiele", "ce:indexed-name": "Simiele M."}, {"@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Calcagno", "ce:indexed-name": "Calcagno A."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Allegra", "ce:indexed-name": "Allegra S."}], "et-al": null}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "[31] Kile, D.A., MaWhinney, S., Aquilante, C.L., Rower, J.E., Castillo-Mancilla, J.R., Anderson, P.L., A population pharmacokinetic\u2013pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 28 (2012), 1227\u20131234.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "A population pharmacokinetic\u2013pharmacogenetic analysis of atazanavir"}, "refd-itemidlist": {"itemid": {"$": "84866696853", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "28"}, "pagerange": {"@first": "1227", "@last": "1234"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.A.", "@_fa": "true", "ce:surname": "Kile", "ce:indexed-name": "Kile D.A."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "MaWhinney", "ce:indexed-name": "MaWhinney S."}, {"@seq": "3", "ce:initials": "C.L.", "@_fa": "true", "ce:surname": "Aquilante", "ce:indexed-name": "Aquilante C.L."}, {"@seq": "4", "ce:initials": "J.E.", "@_fa": "true", "ce:surname": "Rower", "ce:indexed-name": "Rower J.E."}, {"@seq": "5", "ce:initials": "J.R.", "@_fa": "true", "ce:surname": "Castillo-Mancilla", "ce:indexed-name": "Castillo-Mancilla J.R."}, {"@seq": "6", "ce:initials": "P.L.", "@_fa": "true", "ce:surname": "Anderson", "ce:indexed-name": "Anderson P.L."}]}, "ref-sourcetitle": "AIDS Res Hum Retroviruses"}}, {"ref-fulltext": "[32] Rodriguez-Novoa, S., Martin-Carbonero, L., Barreiro, P., Gonzalez-Pardo, G., Jimenez-Nacher, I., Gonzalez-Lahoz, J., et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21 (2007), 41\u201346.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia"}, "refd-itemidlist": {"itemid": {"$": "33845495422", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21"}, "pagerange": {"@first": "41", "@last": "46"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Rodriguez-Novoa", "ce:indexed-name": "Rodriguez-Novoa S."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Martin-Carbonero", "ce:indexed-name": "Martin-Carbonero L."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Barreiro", "ce:indexed-name": "Barreiro P."}, {"@seq": "4", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Gonzalez-Pardo", "ce:indexed-name": "Gonzalez-Pardo G."}, {"@seq": "5", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Jimenez-Nacher", "ce:indexed-name": "Jimenez-Nacher I."}, {"@seq": "6", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Gonzalez-Lahoz", "ce:indexed-name": "Gonzalez-Lahoz J."}], "et-al": null}, "ref-sourcetitle": "AIDS"}}, {"ref-fulltext": "[33] Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 54 (2010), 5242\u20135250.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance"}, "refd-itemidlist": {"itemid": {"$": "78649673343", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "54"}, "pagerange": {"@first": "5242", "@last": "5250"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Schipani", "ce:indexed-name": "Schipani A."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Siccardi", "ce:indexed-name": "Siccardi M."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "D'Avolio", "ce:indexed-name": "D'Avolio A."}, {"@seq": "4", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Baietto", "ce:indexed-name": "Baietto L."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Simiele", "ce:indexed-name": "Simiele M."}, {"@seq": "6", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Bonora", "ce:indexed-name": "Bonora S."}], "et-al": null}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "[34] Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 47 (2008), 1222\u20131225.", "@id": "34", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir"}, "refd-itemidlist": {"itemid": {"$": "53349160769", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47"}, "pagerange": {"@first": "1222", "@last": "1225"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Siccardi", "ce:indexed-name": "Siccardi M."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "D'Avolio", "ce:indexed-name": "D'Avolio A."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Baietto", "ce:indexed-name": "Baietto L."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Gibbons", "ce:indexed-name": "Gibbons S."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Sciandra", "ce:indexed-name": "Sciandra M."}, {"@seq": "6", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Colucci", "ce:indexed-name": "Colucci D."}], "et-al": null}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "[35] Avihingsanon, A., Tongkobpetch, S., Kerr, S.J., Punyawudho, B., Suphapeetiporn, K., Gorowara, M., et al. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr 69 (2015), e36\u20137.", "@id": "35", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia"}, "refd-itemidlist": {"itemid": {"$": "84928422012", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "69"}, "pagerange": {"@first": "e36", "@last": "7"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Tongkobpetch", "ce:indexed-name": "Tongkobpetch S."}, {"@seq": "3", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Kerr", "ce:indexed-name": "Kerr S.J."}, {"@seq": "4", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, {"@seq": "5", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Suphapeetiporn", "ce:indexed-name": "Suphapeetiporn K."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gorowara", "ce:indexed-name": "Gorowara M."}], "et-al": null}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "[36] Dailly, E., Tribut, O., Tattevin, P., Arvieux, C., Perre, P., Raffi, F., et al. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol 62 (2006), 523\u2013526.", "@id": "36", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients"}, "refd-itemidlist": {"itemid": {"$": "33745713170", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62"}, "pagerange": {"@first": "523", "@last": "526"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Dailly", "ce:indexed-name": "Dailly E."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Tribut", "ce:indexed-name": "Tribut O."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Tattevin", "ce:indexed-name": "Tattevin P."}, {"@seq": "4", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Arvieux", "ce:indexed-name": "Arvieux C."}, {"@seq": "5", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Perre", "ce:indexed-name": "Perre P."}, {"@seq": "6", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Raffi", "ce:indexed-name": "Raffi F."}], "et-al": null}, "ref-sourcetitle": "Eur J Clin Pharmacol"}}, {"ref-fulltext": "[37] Taburet, A.M., Piketty, C., Chazallon, C., Vincent, I., Gerard, L., Calvez, V., et al. Interactions between atazanavir\u2013ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 48 (2004), 2091\u20132096.", "@id": "37", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Interactions between atazanavir\u2013ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients"}, "refd-itemidlist": {"itemid": {"$": "2542502584", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "48"}, "pagerange": {"@first": "2091", "@last": "2096"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Taburet", "ce:indexed-name": "Taburet A.M."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Piketty", "ce:indexed-name": "Piketty C."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Chazallon", "ce:indexed-name": "Chazallon C."}, {"@seq": "4", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Vincent", "ce:indexed-name": "Vincent I."}, {"@seq": "5", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Gerard", "ce:indexed-name": "Gerard L."}, {"@seq": "6", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Calvez", "ce:indexed-name": "Calvez V."}], "et-al": null}, "ref-sourcetitle": "Antimicrob Agents Chemother"}}, {"ref-fulltext": "[38] Molt\u00f3, J., Est\u00e9vez, J.A., Miranda, C., Cede\u00f1o, S., Clotet, B., Valle, M., Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients. Br J Clin Pharmacol 82 (2016), 1528\u20131538.", "@id": "38", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients"}, "refd-itemidlist": {"itemid": {"$": "84987994875", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "82"}, "pagerange": {"@first": "1528", "@last": "1538"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Molt\u00f3", "ce:indexed-name": "Molto J."}, {"@seq": "2", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Est\u00e9vez", "ce:indexed-name": "Estevez J.A."}, {"@seq": "3", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Miranda", "ce:indexed-name": "Miranda C."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Cede\u00f1o", "ce:indexed-name": "Cedeno S."}, {"@seq": "5", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Clotet", "ce:indexed-name": "Clotet B."}, {"@seq": "6", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Valle", "ce:indexed-name": "Valle M."}]}, "ref-sourcetitle": "Br J Clin Pharmacol"}}, {"ref-fulltext": "[39] Fournier, C., Higgins, N., Thomas, R., Baril, J.G., Thibeault, D., Lalonde, R., et al. Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir. Ther Drug Monit 35 (2013), 264\u2013269.", "@id": "39", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir"}, "refd-itemidlist": {"itemid": {"$": "84875158790", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "35"}, "pagerange": {"@first": "264", "@last": "269"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Fournier", "ce:indexed-name": "Fournier C."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Higgins", "ce:indexed-name": "Higgins N."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Thomas", "ce:indexed-name": "Thomas R."}, {"@seq": "4", "ce:initials": "J.G.", "@_fa": "true", "ce:surname": "Baril", "ce:indexed-name": "Baril J.G."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Thibeault", "ce:indexed-name": "Thibeault D."}, {"@seq": "6", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Lalonde", "ce:indexed-name": "Lalonde R."}], "et-al": null}, "ref-sourcetitle": "Ther Drug Monit"}}, {"ref-fulltext": "[40] Nettles, R.E., Kieffer, T.L., Parsons, T., Johnson, J., Cofrancesco, J. Jr, Gallant, J.E., et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 42 (2006), 1189\u20131196.", "@id": "40", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring"}, "refd-itemidlist": {"itemid": {"$": "33645797820", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "42"}, "pagerange": {"@first": "1189", "@last": "1196"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.E.", "@_fa": "true", "ce:surname": "Nettles", "ce:indexed-name": "Nettles R.E."}, {"@seq": "2", "ce:initials": "T.L.", "@_fa": "true", "ce:surname": "Kieffer", "ce:indexed-name": "Kieffer T.L."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Parsons", "ce:indexed-name": "Parsons T."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Johnson", "ce:indexed-name": "Johnson J."}, {"@seq": "5", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Cofrancesco", "ce:suffix": "Jr", "ce:indexed-name": "Cofrancesco J."}, {"@seq": "6", "ce:initials": "J.E.", "@_fa": "true", "ce:surname": "Gallant", "ce:indexed-name": "Gallant J.E."}], "et-al": null}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "[41] Crutchley, R.D., Ma, Q., Sulaiman, A., Hochreitter, J., Morse, G.D., Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients. J Pharm Pract 24 (2011), 216\u2013222.", "@id": "41", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients"}, "refd-itemidlist": {"itemid": {"$": "79955566601", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24"}, "pagerange": {"@first": "216", "@last": "222"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.D.", "@_fa": "true", "ce:surname": "Crutchley", "ce:indexed-name": "Crutchley R.D."}, {"@seq": "2", "ce:initials": "Q.", "@_fa": "true", "ce:surname": "Ma", "ce:indexed-name": "Ma Q."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Sulaiman", "ce:indexed-name": "Sulaiman A."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Hochreitter", "ce:indexed-name": "Hochreitter J."}, {"@seq": "5", "ce:initials": "G.D.", "@_fa": "true", "ce:surname": "Morse", "ce:indexed-name": "Morse G.D."}]}, "ref-sourcetitle": "J Pharm Pract"}}, {"ref-fulltext": "[42] Bunupuradah, T., Kiertiburanakul, S., Avihingsanon, A., Chetchotisakd, P., Techapornroong, M., Leerattanapetch, N., et al. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. Lancet HIV 3 (2016), e343\u201350.", "@id": "42", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial"}, "refd-itemidlist": {"itemid": {"$": "84969667316", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "3"}, "pagerange": {"@first": "e343", "@last": "50"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Bunupuradah", "ce:indexed-name": "Bunupuradah T."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Kiertiburanakul", "ce:indexed-name": "Kiertiburanakul S."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, {"@seq": "4", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Chetchotisakd", "ce:indexed-name": "Chetchotisakd P."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Techapornroong", "ce:indexed-name": "Techapornroong M."}, {"@seq": "6", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Leerattanapetch", "ce:indexed-name": "Leerattanapetch N."}], "et-al": null}, "ref-sourcetitle": "Lancet HIV"}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Bangkok", "@id": "60016965", "affilname": "The HIV Netherlands Australia Thailand Research Collaboration", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965", "affiliation-country": "Thailand"}, {"affiliation-city": "Chaing Mai", "@id": "60000881", "affilname": "Chiang Mai University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881", "affiliation-country": "Thailand"}], "coredata": {"srctype": "j", "eid": "2-s2.0-85011066657", "dc:description": "There is evidence that Thai patients receiving standard doses of ritonavir (RTV)-boosted atazanavir (ATV/r) have high exposure to atazanavir (ATV) leading to a higher risk of toxicity. A lower dose of ATV/r may provide adequate exposure in this population. However, pharmacokinetic data on ATV/r in Thai patients required for dose adjustment are limited. This study aimed to develop a population pharmacokinetic model of ATV/r and to determine the influence of patient characteristics on ATV pharmacokinetics. Monte Carlo simulations were performed to estimate the proportion of patients achieving target ATV trough concentration (Ctrough) with the standard ATV/r dose of 300/100 mg and a low dose of 200/100 mg once daily (OD). A total of 127 Thai HIV-infected patients were included in this study. One random blood sample was collected to determine ATV and RTV concentrations at each clinic visit from 100 patients. Intensive data from 27 patients enrolled in previous studies were also included. Data were analysed using the non-linear mixed-effects modelling approach. A one-compartment model with first-order absorption and elimination and absorption lag time best described the data. The population mean clearance of ATV/r was 4.93 L/h in female patients and was 28.7% higher in male patients. Simulation results showed a higher proportion of patients achieving ATV Ctrough within the target range with ATV/r 200/100 mg compared with 300/100 mg. The 200/100 mg OD dose of ATV/r provides adequate ATV exposure in Thai HIV-infected patients. Therefore, a lower dose of ATV/r should be considered for Thai and Asian populations.", "pubmed-id": "28109702", "prism:coverDate": "2017-03-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85011066657", "dc:creator": {"author": [{"ce:given-name": "Baralee", "preferred-name": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, "@seq": "1", "ce:initials": "B.", "@_fa": "true", "affiliation": {"@id": "60000881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"}, "ce:surname": "Punyawudho", "@auid": "23976628300", "author-url": "https://api.elsevier.com/content/author/author_id/23976628300", "ce:indexed-name": "Punyawudho B."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/85011066657"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85011066657&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85011066657&origin=inward"}], "source-id": "19757", "pii": "S0924857917300122", "citedby-count": "7", "prism:volume": "49", "subtype": "ar", "dc:title": "Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients", "openaccess": "0", "prism:issn": "18727913 09248579", "publishercopyright": "\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy", "prism:issueIdentifier": "3", "subtypeDescription": "Article", "prism:publicationName": "International Journal of Antimicrobial Agents", "prism:pageRange": "327-332", "prism:endingPage": "332", "openaccessFlag": "false", "prism:doi": "10.1016/j.ijantimicag.2016.11.019", "prism:startingPage": "327", "dc:identifier": "SCOPUS_ID:85011066657", "dc:publisher": "Elsevier B.V."}, "idxterms": {"mainterm": [{"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Anti-HIV Agents", "@weight": "b", "@candidate": "n"}, {"$": "Atazanavir Sulfate", "@weight": "b", "@candidate": "n"}, {"$": "Blood Chemical Analysis", "@weight": "b", "@candidate": "n"}, {"$": "Cross-Sectional Studies", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "HIV Infections", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Middle Aged", "@weight": "b", "@candidate": "n"}, {"$": "Monte Carlo Method", "@weight": "b", "@candidate": "n"}, {"$": "Ritonavir", "@weight": "b", "@candidate": "n"}, {"$": "Thailand", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "Atazanavir"}, {"@_fa": "true", "$": "Dose optimisation"}, {"@_fa": "true", "$": "HIV-infected patients"}, {"@_fa": "true", "$": "NONMEM"}, {"@_fa": "true", "$": "Population pharmacokinetics"}, {"@_fa": "true", "$": "Thai patients"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Microbiology (medical)", "@code": "2726", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Infectious Diseases", "@code": "2725", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Pharmacology (medical)", "@code": "2736", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Baralee", "preferred-name": {"ce:given-name": "Baralee", "ce:initials": "B.", "ce:surname": "Punyawudho", "ce:indexed-name": "Punyawudho B."}, "@seq": "1", "ce:initials": "B.", "@_fa": "true", "affiliation": {"@id": "60000881", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881"}, "ce:surname": "Punyawudho", "@auid": "23976628300", "author-url": "https://api.elsevier.com/content/author/author_id/23976628300", "ce:indexed-name": "Punyawudho B."}, {"ce:given-name": "Narukjaporn", "preferred-name": {"ce:given-name": "Narukjaporn", "ce:initials": "N.", "ce:surname": "Thammajaruk", "ce:indexed-name": "Thammajaruk N."}, "@seq": "2", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, "ce:surname": "Thammajaruk", "@auid": "36451572800", "author-url": "https://api.elsevier.com/content/author/author_id/36451572800", "ce:indexed-name": "Thammajaruk N."}, {"ce:given-name": "Kiat", "preferred-name": {"ce:given-name": "Kiat", "ce:initials": "K.", "ce:surname": "Ruxrungtham", "ce:indexed-name": "Ruxrungtham K."}, "@seq": "3", "ce:initials": "K.", "@_fa": "true", "affiliation": [{"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}], "ce:surname": "Ruxrungtham", "@auid": "7004208798", "author-url": "https://api.elsevier.com/content/author/author_id/7004208798", "ce:indexed-name": "Ruxrungtham K."}, {"ce:given-name": "Anchalee", "preferred-name": {"ce:given-name": "Anchalee", "ce:initials": "A.", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, "@seq": "4", "ce:initials": "A.", "@_fa": "true", "affiliation": [{"@id": "60016965", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"}, {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}], "ce:surname": "Avihingsanon", "@auid": "57196347321", "author-url": "https://api.elsevier.com/content/author/author_id/57196347321", "ce:indexed-name": "Avihingsanon A."}]}}}